Investigational drug · Phase 2
Merestinib
Also called: LY2801653
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
10
Any phase or sponsor naming "Merestinib"
First trial start
2016
May 19, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Merestinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Cancer
- Metastatic Cancer
- Advanced Cancer
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Merestinib" as an intervention, largest first.
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT02711553 · 309 participants · Start May 19, 2016 · Primary completion Feb 16, 2018
Drug: Ramucirumab; Merestinib and 4 more · For: Biliary Tract Cancer; Metastatic Cancer; Advanced Cancer
Sites: Tucson, Arizona; San Francisco, California; Washington D.C., District of Columbia · 82 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT01285037 · 190 participants · Start Sep 9, 2009 · Primary completion Jul 21, 2017
Drug: LY2801653; Cetuximab and 3 more · For: Cancer
Sites: Tucson, Arizona; Washington D.C., District of Columbia; New York, New York · 7 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT02791334 · 164 participants · Start Jun 29, 2016 · Primary completion May 22, 2020
Drug: LY3300054; Ramucirumab and 3 more · For: Solid Tumor; Microsatellite Instability-High (MSI-H) Solid Tumors; Cutaneous Melanoma and 2 more
Sites: Nashville, Tennessee; Houston, Texas; San Antonio, Texas · 14 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT02779738 · 24 participants · Start May 2016 · Primary completion Aug 2016
Drug: Merestinib · For: Healthy
Sites: Daytona Beach, Florida
Eli Lilly and CompanyEli Lilly (LLY)
NCT02370485 · 23 participants · Start Feb 2015 · Primary completion May 2015
Drug: LY2801653 · For: Healthy
Sites: Daytona Beach, Florida
Eli Lilly and CompanyEli Lilly (LLY)
NCT02745769 · 23 participants · Start Oct 21, 2016 · Primary completion Nov 5, 2018
Drug: Ramucirumab; Merestinib and 1 more · For: Advanced Cancer; Colorectal Cancer; Mantle Cell Lymphoma
Sites: Birmingham, Alabama; Houston, Texas; Lyon, France · 5 sites in all
- A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03027284 · 19 participants · Start Feb 3, 2017 · Primary completion Jun 20, 2019
Drug: Merestinib; Cisplatin and 1 more · For: Advanced Cancer; Metastatic Cancer; Biliary Tract Carcinoma and 4 more
Sites: Chiba, Japan; Tokyo, Japan
- Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompleted
Jacqueline Garcia, MDAcademic, hospital or other
NCT03125239 · 16 participants · Start Aug 10, 2017 · Primary completion Jun 1, 2020
Drug: Merestinib; LY2874455 · For: Relapsed Adult Acute Myeloid Leukemia; Refractory Adult Acute Myeloid Leukemia
Sites: Boston, Massachusetts · 2 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT02920996 · 12 participants · Start Nov 11, 2016 · Primary completion Oct 2021
Drug: Merestinib · For: Carcinoma, Non-Small-Cell Lung; Solid Tumor
Sites: Boston, Massachusetts · 2 sites in all
University of UtahAcademic, hospital or other
NCT03292536 · 2 participants · Start Jan 11, 2018 · Primary completion Jun 24, 2019
Drug: Merestinib · For: Bone Metastases; Breast Cancer
Sites: Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacologically targeting CDK12 induces BRCAness and synergizes with merestinib to exacerbate DNA damage in high-risk neuroblastoma.
Goulding JR, Couwenbergh ST, Bekaert SL, et al. · Cell Rep 2026
- Copper homeostasis and cuproptosis: New perspectives on the diagnosis and treatment of metabolic diseases.
Chen J, Fang C, Tang S, et al. · J Trace Elem Med Biol 2026
- Targeting the c-Met/VEGFR Pathway to Boost Nab-Paclitaxel Efficacy in Gastric Cancer: Preclinical Insights.
Huang J, Kaurich Q, Hassan MS, et al. · Cells 2026
- Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming.
Fang W, Kozai Y, Acevedo DS, et al. · Cancer Biol Ther 2025
- Gut microbial metabolite, sphingosine-1-phosphate (S1P), drives mesangial cell phenotypic transformation and accelerates progression of IgA nephropathy via CCL2-MET-FAK pathway.
Tang YY, Zhang DL, Huang LS, et al. · Curr Res Microb Sci 2025
- From Gene Networks to Therapeutics: A Causal Inference and Deep Learning Approach for Drug Discovery.
Ghandikota S, Jegga AG · Pharmaceuticals (Basel) 2025
Also in development for Biliary Tract Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.